触媒制药 CPRX 深 沪
已收盘 08-08 16:00:00 美东时间
19.86
+0.225
+1.15%
华盛通- 最 高20.0785
- 今 开19.70
- 成交量 223.70万股
- 最 低 19.48
- 昨 收 19.635
- 总市值 24.23亿
- 52周最高 26.58
- 市盈率 静 15.14
- 换手率 1.83%
- 52周最低 19.00
- 委 比 -85.11%
- 总股本 1.22亿
- 历史最高 26.58
- 量 比 1.17
- 振 幅 3.05%
- 历史最低 0.37
- 每 手 1
- 风险率 1.60%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA
<p>Capricor Therapeutics has postponed its Q2 2025 financial results release to August 11, 2025, due to a scheduled FDA meeting about its Deramiocel therapy for DMD-associated cardiomyopathy. A webcast and conference call will review financials and provide updates at 4:30 p.m. ET on August 11.</p>
08-08 12:30
Catalyst Pharma Updates Guidelines for SCLC Treatment
Catalyst Pharma ( ($CPRX) ) just unveiled an announcement. On August 6, 2025, C...
08-08 05:49
Catalyst Pharmaceuticals shares are trading lower. The company reported Q2 financial results.
Catalyst Pharmaceuticals shares are trading lower. The company reported Q2 fina...
08-08 00:31
Milestone Achievement for Hospital Using Catheter Precision’s VIVO System
Heart Hospital of New Mexico has become the first to complete 200 ventricular ablation procedures using Catheter Precision's VIVO system. The VIVO system is a non-invasive 3D imaging tool designed to identify the origin of ventricular arrhythmias pre-procedure, improving workflow and reducing procedure time. Catheter Precision's CEO, David Jenkins, congratulated the hospital for embracing the technology and achieving this milestone. The hospital,...
08-07 12:00
Catalyst Pharmaceuticals Affirms FY2025 Sales Guidance of $545.000M-$565.000M vs $561.012M Est
Catalyst Pharmaceuticals (NASDAQ:CPRX) affirms FY2025 sales outlook from $545.000 million-$565.000 million to $545.000 million-$565.000 million vs $561.012 million estimate.
08-07 04:24
Catalyst Pharmaceuticals Q2 Adj. EPS $0.68 Beats $0.38 Estimate, Sales $146.563M Beat $140.418M Estimate
Catalyst Pharmaceuticals (NASDAQ:CPRX) reported quarterly earnings of $0.68 per share which beat the analyst consensus estimate of $0.38 by 77.08 percent. This is a 21.43 percent increase over earnings of $0.56 per share
08-07 04:23
Catalyst Pharmaceuticals Applauds NCCN Guideline Update Adding LEMS Diagnosis And Amifampridine Support For SCLC Patients
VGCC antibody testing in conjunction with neurologic consultation can diagnose LEMSAmifampridine may be considered as a supportive care treatmentGuideline inclusion may raise clinical awareness of cancer-associated LEMS
08-06 20:18
Earnings Scheduled For August 6, 2025
Companies Reporting Before The Bell • Lineage (NASDAQ:LINE) is likely to report...
08-06 16:33
Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13
<p>Capricor Therapeutics will release its second quarter 2025 financial results on August 13, 2025, followed by a conference call and webcast at 4:30 p.m. ET. The call can be accessed via toll-free (1-800-717-1738) or international numbers (1-646-307-1865), conference ID 90328, or via the provided webcast link. Additional details about the company and its pipeline, including Deramiocel for Duchenne Muscular Dystrophy, are available on its website...
08-06 13:00
Lambert Eaton Myasthenic Syndrome (LEMS) Antibody Testing and Treatment Recommendations Added to NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC)
Catalyst Pharmaceuticals announced that the updated NCCN Clinical Practice Guidelines for Small Cell Lung Cancer (SCLC) now include Lambert Eaton myasthenic syndrome (LEMS), amifampridine, and VGCC antibody testing. The guidelines recommend neurological evaluation and VGCC antibody testing for diagnosing LEMS, with amifampridine as a supportive treatment option. Approximately 50% of LEMS cases are associated with cancer, commonly SCLC, but many r...
08-06 12:03
